IPSC

#3144
Century Therapeutics, Inc. - Common Stock
2.0 3 USD
-0.09%
Market Price
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
2.03
2.03
Yıllık Aralık
0.44
3.03
Günlük Değişim
-8.97%
Aylık Değişim
-6.88%
6 Aylık Değişim
-9.38%
Yıllık Değişim
+314.29%
Önceki Kapanış
2.2 3
Open
2.0 3
Düşük
2.0 3
Yüksek
2.0 3
Hacim
34
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Documents

2026

Current report, Q3 FY2026
Century Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Century Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Century Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K

Century Therapeutics, Inc. current report, Q3 FY2025

Full document

Century Therapeutics, Inc. (IPSC) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Century Therapeutics, Inc. on August 27, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Philadelphia, Pennsylvania. The report addresses a material event regarding the Company's listing status on The Nasdaq Stock Market.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance metrics.

Material Changes

  • Delisting Notice: On February 26, 2025, the Company received a deficiency letter from Nasdaq for failing to meet the $1.00 minimum bid price requirement (Rule 5450(a)(1)) for 30 consecutive business days.
  • Transfer of Listing: As the Company did not regain compliance by the initial deadline of August 26, 2025, Nasdaq approved the transfer of the Company's common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective August 27, 2025.
  • Trading Symbol: The common stock continues to trade under the symbol "IPSC."

Guidance, Outlook, and Risks

  • Compliance Extension: Nasdaq granted the Company an additional 180-day period to regain compliance with the $1.00 minimum bid price rule, extending the deadline to February 23, 2026.
  • Remediation Strategy: The Company intends to monitor its stock price and may consider a reverse stock split to cure the deficiency.
  • Risks: There is no assurance that the Company will be able to regain compliance with the Bid Price Rule or other listing criteria before the extended deadline. Failure to comply could result in delisting.

Investor Verification Checklist

  • Verify the current closing bid price of IPSC to assess proximity to the $1.00 compliance threshold.
  • Monitor future filings for announcements regarding a potential reverse stock split.
  • Confirm the Company's continued compliance with other Nasdaq Capital Market listing requirements (e.g., market value of publicly held shares).
  • Review the Company's cash position in subsequent filings to ensure sufficient liquidity to fund operations while addressing listing issues.

Haberler